Beyond hypertension: Toward guidelines for cardiovascular risk reduction

American Journal of Hypertension

Volumn 17, Issue 11, 2004, Pages 1068-1074

  Volpe, Massimo ^a,i   Alderman, Michael H ^b   Furberg, Curt D ^c   Jackson, Rodney ^d   Kostis, John B ^e   Laragh, John H ^f   Psaty, Bruce M ^g   Ruilope, Luis M ^h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Fac Med Hlth Sci Univ A   (New Zealand)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular disease; cardiovascular risk; diabetes; hypercholesterolemia; hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS;

EID: 7944220524     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.06.017     Document Type: Review

References (48)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
2. S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins Age-specific relevance of usual blood pressure to vascular mortality a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
3. M.R. Law, N.J. Wald Risk factor thresholds their existence under scrutiny Br Med J 324 2002 1570 1576
4. P.C. van den Hoogen, E.J. Feskens, N.J. Nagelkerke, A. Menotti, A. Nissinen, D. Kromhout The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group N Engl J Med 342 2000 1 8
5. Blood Pressure Lowering Treatment Trialists' Collaboration Effect of angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs results of prospectively designed overviews of randomized trials Lancet 355 2000 1955 1964
6. S. Yusuf, P. Sleight, G. Dagenais, T. Montague, J. Bosh, J. Pogue, W. Taylor, L. Sardo Hearth Outcomes Prevention Evaluation (HOPE) Study Group Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
7. PROGRESS Collaborative Group Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
8. J.D. Neaton, D. Wentworth Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group Arch Intern Med 152 1992 56 64
9. K.M. Anderson, P.M. Odell, P.W. Wilson, W.B. Kannel Cardiovascular disease risk profile Am Heart J 121 1991 293 298
10. C.D. Mulrow, J.A. Cornell, C.R. Herrera, A. Kadri, L. Farnett, C. Aguilar Hypertension in the elderly. Implications and generalizability of randomized trials JAMA 272 1994 1932 1938
11. S.J. Pocock, V. McCormack, F. Gueyffier, F. Boutitie, R.H. Fagard, J.P. Boissel A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomized controlled trials Br Med J 323 2001 75 81
12. A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, D. Jones, B. Materson, S. Oparil, J. Wright, E. Roccella The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report JAMA 289 2003 2560 2571
13. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 6 2003 1011 1053
14. R. Jackson Updated New Zealand cardiovascular disease risk-benefit prediction guide Br Med J 320 2000 709 710
15. E.J. Wallis, L.E. Ramsay, I. Ul Haq, P. Ghahramani, P.R. Jackson, K. Rowland-Yeo, W.W. Yeo Coronary and cardiovascular risk estimation for primary prevention validation of a new Sheffield table in the 1995 Scottish Health Survey population Br Med J 320 2000 671 676
16. British Cardiac Society British Hyperlipidaemia Association British Hypertension Society British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice summary BMJ 320 2000 705 708
17. S. MacMahon, R. Peto, J. Cutler, R. Collins, P. Sorlie, J. Neaton, R. Abbott, J. Godwin, A. Dyer, J. Stamler Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure prospective observational studies corrected for the regression dilution bias Lancet 335 1990 765 774
18. K.R. Yeo, W.W. Yeo Should we treat high-normal blood pressure? J Hypertens 20 2002 2057 2062
19. United Kingdom Prospective Diabetes Study Group (UKPDS) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS38 Br Med J 317 1998 703 713
20. Hypertension Detection and Follow-up Program Cooperative Group, 1979 Five-year findings of the hypertension detection and follow-up program. Reduction in mortality of persons with high blood pressure, including mild hypertension JAMA 277 2 1997 157 166
21. E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IRMA 2) N Engl J Med 345 2001 851 860
22. S.A. Grover, K. Gray-Donald, L. Joseph, M. Abrahamowicz, L. Coupal Life expectancy following dietary modification or smoking cessation estimating the benefits of a prudent lifestyle Arch Intern Med 154 1994 1697 1704
23. SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1991 1667
24. S.A. Grover, K. Gray-Donald, L. Joseph, M. Abrahamowicz, L. Coupal Life expectancy following dietary modification or smoking cessation estimating the benefits of a prudent lifestyle Arch Intern Med 154 1994 1697 1704
25. P.R. Hebert, J.M. Gaziano, K.S. Chan, C.H. Hennekens Cholesterol lowering with statin drugs, risk of stroke, and total mortality an overview of randomized trials JAMA 278 1997 313 321
26. M. Pignone, C. Phillips, C. Mulrow Use of lipid lowering drugs for primary prevention of coronary heart disease meta-analysis of randomized trials Br Med J 321 2000 983 986
27. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial Lancet 360 9326 2002 7 22
28. P. Sever, B. Dahlöf, N. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Östergren ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial Lancet 361 2003 1149 1158
29. M. Hayden, M. Pignone, C. Phillips, C. Mulrow Aspirin for the primary prevention of cardiovascular events a summary of the evidence for the US Preventive Services Task Force Ann Intern Med 136 2002 161 172
30. C. Patrono, B. Coller, J.E. Dalen, G.A. Fitz Gerald, V. Fuster, M. Gent, J. Hirsh, G. Roth Platelet-active drugs the relationship among dose effectiveness and side effects Chest 119 Suppl 1 2001 395 412
31. N.J. Wald, M.R. Law A strategy to reduce cardiovascular disease by more than 80% Br Med J 326 2003 1419 1424
32. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
33. B.M. Psaty, N.L. Smith, D.S. Siscovick, T.D. Koepsell, N.S. Weiss, S.R. Heckbert, R.N. Lemaitre, E.H. Wagner, C.D. Furberg Health outcomes associated with anti-hypertensive therapies used as first-line agents a systematic review and meta-analysis JAMA 277 1997 739 745
34. B.M. Psaty, N.S. Weiss, C.D. Furberg, T.D. Koepsell, D.S. Siscovick, F.R. Rosendaal, N.L. Smith, S.R. Heckbert, R.C. Kaplan, D. Lin, T.R. Fleming, E.H. Wagner Surrogate endpoints, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease JAMA 282 1999 786 790
35. L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlof, D. Elmfeldt, S. Julius, J. Menard, K.H. Rahn, H. Wedel, S. Westerling Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 9118 1998 1755 1762
36. J.T. Wright Jr, G. Bakris, T. Greene, L.Y. Agodoa, L.J. Appel, J. Charleston, D. Cheek, J.G. Douglas-Baltimore, J. Gassman, R. Glassock, L. Hebert, K. Jamerson, J. Lewis, R.A. Phillips, R.D. Toto, J.P. Middleton, S.G. Rostand African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease results from the AASK trial JAMA 288 19 2002 2421 2431
37. R. Voss, P. Cullen, H. Schulte, G. Assmann Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks Int J Epidemiol 31 2002 1253 1262
38. H. Tunstal-Pedoe The Dundee coronary risk-disk for management of change in risk factors Br Med J 303 1991 744 747
39. R.M. Conroy, K. Pyörälä, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer, D. De Bacquer, P. Ducimetière, P. Jousilahti, U. Keil, I. Njølstad, R.G. Oganov, T. Thomsen, H. Tunstall-Pedoe, A. Tverdal, H. Wedel, P. Whincup, L. Wilhelmsen, I.M. Graham Estimation of ten-year risk of fatal cardiovascular disease in Europe the SCORE project Eur Heart J 24 2003 987 1003
40. Diverse Populations Collaborative Group Prediction of mortality from coronary heart disease among diverse populations is there a common predictive function? Heart 88 2002 222 228
41. J.S. Yudkin, N. Chaturvedi Developing risk stratification charts for diabetic and non-diabetic subjects Diabet Med 16 1999 219 227
42. R.B. D'Agostino, M.W. Russell, D.M. Huse, R.C. Ellison, H. Silbershatz, P.W. Wilson, S.C. Hartz Primary and subsequent coronary risk appraisal new results from the Framingham study Am Heart J 139 2000 272 278
43. P.M. Ridker Role of inflammatory biomarkers in prediction of coronary artery disease Lancet 358 2001 946 948
44. J.R. Emberson, P.H. Whincup, R.W. Morris, M. Walker Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the etiology of coronary heart disease impact of regression dilution bias Eur Heart J 24 2003 1719 1726
45. A.S. Wierzbicki, T.M. Reynolds, K. Gill, S. Alg, M.A. Crook A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease J Cardiovasc Risk 7 2000 63 71
46. P. Brindle, J. Emberson, F. Lampe, M. Walker, P. Whincup, T. Fahey, S. Ebrahim Predictive accuracy of the Framingham coronary risk score in British men prospective cohort study Br Med J 327 2003 1238 1239
47. C.L. de Visser, H.J. Bilo, T.F. Thomsen, K.H. Groenier, Jong Meyboom-de Prediction of coronary heart disease a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population J Intern Med 253 2003 553 562
48. L.M. Ruilope, A. Coca, M. Volpe, B. Waeber ACE inhibition and cardiovascular mortality and morbidity in essential hypertension the end of the search or a need for further investigations? Am J Hypertens 15 2002 367 371